STRN
Overview
STRN (striatin) encodes a calmodulin-binding protein that serves as a scaffold of the STRIPAK (striatin-interacting phosphatase and kinase) complex. In cancer genomics, STRN is notable as a fusion partner of ALK, forming the STRN-ALK fusion that constitutively activates ALK kinase signaling. This fusion has been identified in thyroid cancer and other tumor types.
Alterations observed in the corpus
- ALK-STRN fusion identified in PDTC (poorly differentiated thyroid carcinoma) in a targeted sequencing cohort studying thyroid cancer progression PMID:26878173
Cancer types (linked)
- Thyroid cancer (PDTC/ATC): STRN acts as ALK fusion partner (ALK-STRN) in a subset of poorly differentiated thyroid carcinomas; fusions were identified alongside ALK-EML4 and a novel ALK-CCDC149 variant PMID:26878173
Co-occurrence and mutual exclusivity
- ALK fusions (including ALK-STRN) are mutually exclusive with BRAF and RAS mutations and with other gene fusions in thyroid cancer PMID:26878173
Therapeutic relevance
- As an ALK fusion partner, ALK-STRN tumors may be candidates for ALK-targeted therapies; no direct drug evidence from this study PMID:26878173
Open questions
- The clinical behavior of STRN-ALK fusion-positive thyroid tumors relative to other ALK fusions (EML4-ALK, CCDC149-ALK) is not characterized in this cohort PMID:26878173
Sources
This page was processed by crosslinker on 2026-05-14.